Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
View Patent ↗A small number of defined antigens can provide broad protection against meningococcal infection, and the invention provides a composition which, after administration to a subject, is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against two or three of hypervirulent lineages A4, ET 5 and lineage 3 of N. meningitidis serogroup B. Rather than consisting of a single antigen, the composition comprises a mixture of 10 or fewer purified antigens, and should not include complex or undefined mixtures of antigens such as outer membrane vesicles. Five protein antigens are used in particular: (1) a ‘NadA’ protein; (2) a ‘741’ protein; (3) a ‘936’ protein; (4) a ‘953’ protein; and (5) a ‘287’ protein.
1. An immunogenic composition comprising at least the following three Neisserial antigens: NadA, 287, and 741, wherein each of the three Neisserial antigens is purified and wherein said immunogenic composition also comprises an outer-membrane vesicle (OMV) preparation from N. meningitidis.
2. The immunogenic composition of claim 1 , wherein the outer-membrane vesicle is obtained from N. meningitidis strain H44/76 or 394/98.
3. The immunogenic composition of claim 1 , wherein the outer-membrane vesicle is obtained from N. meningitidis strain H44/76.
4. The immunogenic composition of any one of claims 1 - 3 , further comprising an antigen from N. meningitidis.
5. The immunogenic composition of any one of claims 1 - 3 , wherein all of the Neisserial antigens are N. meningitidis antigens.
6. The immunogenic composition of any one of claims 1 - 3 , further comprising one or more saccharide antigens from N. meningitidis.
7. The immunogenic composition of claim 6 , wherein the one or more saccharides antigens are from N. meningitidis serogroup A, C, W135 and/or Y.
8. The immunogenic composition of any one of claims 1 - 3 , further comprising an adjuvant.
9. The immunogenic composition of claim 8 , wherein the adjuvant is aluminum salt.
10. The immunogenic composition of claim 8 , wherein the adjuvant is aluminum hydroxide gel.